The Japanese government is aware of the challenges in securing funds for drug development within Japan’s biopharmaceutical startup ecosystem, especially compared to Europe and the United States. The Japan Agency for Medical Research and Development has established a program to support biopharmaceutical startups involved in developing patentable pharmaceuticals and regenerative medicine products and therapeutics.
Continue Reading Japan’s AMED Offers ‘Double Match Up’ Grants for Pharma Startups: Considerations for Investors and Companies
There is a self-selection factor rewarding start-ups. Specifically, they can’t attract funding or licensing deals unless they’ve protected their intellectual property, showed